STEAP4 as A Potential Drug Target for HCC (G79689)

Target Name: STEAP4

NCBI ID: G79689

STEAP4

STEAP4 as A Potential Drug Target for HCC

STEAP4, also known as Seven chromosome locus associated with hepatocellular carcinoma (HCC), is a gene that has been identified as a potential drug target or biomarker for the treatment of HCC. HCC is a type of liver cancer that is characterized by the formation of tumors on the liver cells, and it is one of the leading causes of cancer-related deaths worldwide.

The STEAP4 gene was identified as a potential drug target for HCC due to its involvement in the development and progression of the disease. The STEAP4 gene is located on the seventh chromosome, which is one of the most commonly deleted chromosomes in the human genome . Studies have shown that individuals with certain genetic variations, including those found in the STEAP4 gene, are at an increased risk of developing HCC.

In addition to its potential as a drug target, the STEAP4 gene has also been shown to be a potential biomarker for HCC. The STEAP4 gene has been shown to be expressed in a variety of tissues and cells, including liver cells, peroxidase cells, and blood vessels. Additionally, the gene has been shown to be involved in the development and progression of HCC, and has been shown to be a potential target for drugs that can inhibit its activity.

Despite the potential benefits of targeting the STEAP4 gene, there are also potential drawbacks to consider. For example, the gene has not yet been fully characterized, and it is not yet clear exactly how it is involved in the development and progression of HCC. Additionally , it is not yet clear how targeting the STEAP4 gene will be effective in treating HCC, or what the optimal approach to treatment will be.

Overall, the STEAP4 gene is a promising target for the development of new drugs for the treatment of HCC. Further research is needed to fully understand its role in the disease and to develop effective treatments.

Protein Name: STEAP4 Metalloreductase

Functions: Integral membrane protein that functions as NADPH-dependent ferric-chelate reductase, using NADPH from one side of the membrane to reduce a Fe(3+) chelate that is bound on the other side of the membrane. Mediates sequential transmembrane electron transfer from NADPH to FAD and onto heme, and finally to the Fe(3+) chelate (PubMed:30337524). Can also reduce Cu(2+) to Cu(1+) (By similarity). Plays a role in systemic metabolic homeostasis, integrating inflammatory and metabolic responses (By similarity). Associated with obesity and insulin-resistance (PubMed:18430367, PubMed:18381574). Involved in inflammatory arthritis, through the regulation of inflammatory cytokines (PubMed:19660107). Inhibits anchorage-independent cell proliferation (PubMed:19787193)

The "STEAP4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STEAP4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets